Enter multiple symbols separated by commas

Stocks Allergan Inc


  • Hedgies all-in on stocks; here's how to play it Monday, 23 Feb 2015 | 1:19 PM ET
    Traders on the floor of the New York Stock Exchange.

    Allocations in the industry have turned to their most bullish positions ever, with a net-long exposure of 57 percent.

  • NEW YORK, Feb 22- Canada's Valeant Pharmaceuticals International Inc. agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd. in an all-cash deal valued at about $10.1 billion, the two companies said on Sunday. The deal is the largest ever for Laval, Quebec- based Valeant, which lost a take-over contest for Allergan Inc last year.

  • Drugmaker Valeant to buy Salix: Sources Saturday, 21 Feb 2015 | 2:55 PM ET

    The all-cash deal could be announced as soon as Sunday, according to these sources who requested not to be identified.

  • NEW YORK, Feb 20- Valeant Pharmaceuticals International Inc is close to a deal to acquire bowel drug maker Salix Pharmaceuticals Ltd for around $160 per share, according to a person directly familiar with the matter. A deal of that size would be the largest ever for Valeant, which lost a takeover contest for Allergan Inc last year. The usually acquisitive Valeant...

  • Forget Buffett. Follow these top investors Wednesday, 18 Feb 2015 | 12:46 PM ET
    Jeffrey Smith, Starboard Value

    CNBC.com found the best performing investors you probably have never heard of, but are beating the market these days. Here are their top picks.

  • NEW YORK, Feb 18- Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs. Actavis, which began as a New Jersey- based generics company called Watson, took its current...

  • UPDATE 2-Actavis beats profit estimates, raises forecast Wednesday, 18 Feb 2015 | 9:11 AM ET

    Feb 18- Actavis Plc posted a better-than-expected adjusted quarterly profit and raised its full-year earnings forecast, saying it expected strong sales of its new branded drugs. Actavis agreed to buy Allergan Inc last November for $66 billion, outbidding a hostile offer by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

  • Actavis to take Allergan name Wednesday, 18 Feb 2015 | 7:42 AM ET
    Actavis to take Allergan name

    Actavis President & CEO Brent Saunders explains the new corporate name, and the strong earnings beat. "We keep surprising people," says Saunders.

  • Actavis, which bought Botox-maker Allergan Inc in November, makes drugs from research in its own pipeline, and copy cat versions of other popular drugs. Sales of the Actavis's branded drugs nearly tripled to $1.83 billion in North America in the fourth quarter, accounting for 45 percent of total revenue. For the fourth quarter ended Dec. 31, Actavis's net loss...

  • Two billionaires, opposite approaches to investing Friday, 13 Feb 2015 | 2:25 PM ET
    Ray Dalio, left, and Bill Ackman

    It was man versus machine when Bill Ackman interviewed Ray Dalio in New York.

  • Allergan CEO: Bill Ackman battle was all-consuming Tuesday, 10 Feb 2015 | 9:36 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Allergan chief David Pyott tells CNBC that dealing with "raiders" like Bill Ackman and Valeant Pharmaceuticals was a full-time job.

  • Allergan CEO: Fighting Ackman 'all consuming' Tuesday, 10 Feb 2015 | 8:03 AM ET
    Allergan CEO: Fighting Ackman 'all consuming'

    David Pyott, Allergan chairman & CEO, discusses the company's historic quarter, Bill Ackman's failed attempt to take over the company and the decision to subdivide the management team.

  • WASHINGTON, Feb 10- For the first time in 20 years, patients suffering from the eye disease glaucoma may soon have new treatments as several young companies look to shake up the $5.6 billion global market. No new class of medicine has been introduced since Pfizer Inc's N> Xalatan, known generically as latanoprost, in 1996.. The newcomers aim to disrupt...

  • A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    M&A experts forecast there will be more major pharma deals in 2015 — but the U.K. won’t be a focus and the deals won’t be done for tax reasons.

  • Early movers: HSP, LB, SIRI, YUM, CME & more Thursday, 5 Feb 2015 | 7:49 AM ET
    NYSE New York Stock Exchange traders markets

    Some of the names on the move ahead of the open.

  • Bill Ackman takes a break—for now Monday, 2 Feb 2015 | 12:37 PM ET
    Bill Ackman joins Squawk Box on their first day at their new set in New York City.

    Bill Ackman appears set to take it easy for a few months after knockout performance in 2014.

  • Big deals aside, Actavis CEO says it's R&D over M&A Friday, 30 Jan 2015 | 9:07 AM ET
    Actavis Group headquarters is shown in Hafnarfjordur, Iceland, April 20, 2006.

    The drugmaker has engaged in $100 billion of M&A in the last year, but CEO Brent Saunders told CNBC it is committed to innovation.

  • Davos: Why M&A won't go away Friday, 23 Jan 2015 | 2:40 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Activist shareholders in 2014 helped the mergers and acquisitions landscape return to the pre-crisis days of 2007 – and they'll continue to make news.

  • Bill Ackman: Herbalife short was 'philanthropic' Wednesday, 14 Jan 2015 | 4:39 AM ET
    Bill Ackman joins Squawk Box on their first day at their new set in New York City.

    Activist investor famous for his high-profile battle with Herbalife claims short was 'most philanthropic investment I have ever made.'

  • Valeant CEO: Allegations about our business not true Tuesday, 13 Jan 2015 | 12:46 PM ET
    Valeant CEO: Allegations about our business not true

    Valeant CEO Mike Pearson tells CNBC's Meg Tirrell the company is on a mission to prove allegations against the business model are not true. Pearson says Valeant is unlikely to work with Bill Ackman.